Evidence mapPaperPMID 41849133Full record

Observational studyHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2026

Lipoprotein(a) in Essential Hypertension: Associations with Blood Pressure and Hypertension-Mediated Organ Damage.

Giulia Nardoianni, Giuliano Tocci, Barbara Pala, Marco Russo, Giovanni Marco Dutti, Federica Fogacci, Arrigo F G Cicero, Massimo Volpe, Emanuele Barbato

Abstract readObservational Study
In one paragraph

Observational study in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giulia Nardoianni *Division of Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy.ORCID http://orcid.org/0000-0001-6861-6870
Giuliano Tocci *Division of Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy. giuliano.tocci@uniroma1.it.ORCID http://orcid.org/0000-0002-0635-4921
Barbara PalaDivision of Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy.ORCID http://orcid.org/0000-0002-7359-4028
Marco RussoDivision of Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy.
Giovanni Marco DuttiDivision of Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy.
Federica FogacciHypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, University of Bologna, Via Massarenti 9, Bologna, 40138, Italy.ORCID http://orcid.org/0000-0001-7853-0042
Arrigo F G CiceroHypertension and Cardiovascular Risk Research Center, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, University of Bologna, Via Massarenti 9, Bologna, 40138, Italy.ORCID http://orcid.org/0000-0002-4367-3884
Massimo VolpeDivision of Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy.ORCID http://orcid.org/0000-0002-9642-8380
Emanuele BarbatoDivision of Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy.ORCID http://orcid.org/0000-0002-0050-5178

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlthough recommended for cardiovascular (CV) risk stratification in adults, the role of lipoprotein(a) [Lp(a)] in hypertension is not fully established.

aimTo evaluate Lp(a) levels in adult outpatients with essential arterial hypertension.

methodsA retrospective, observational study was conducted in outpatients of both sexes, aged ≥ 18 years, with treated or untreated essential hypertension, who were consecutively evaluated at the Hypertension Unit, Excellence Hypertension Center, Sant'Andrea Hospital, Rome, Italy. Participants underwent office and out-of-office blood pressure (BP) measurements, as well as assessment of hypertension-mediated organ damage (HMOD). BP measurements were performed, and hypertension phenotypes were classified according to 2023 European hypertension guidelines. Lp(a) levels were measured, and the study population was stratified according to a Lp(a) cut-off value of ≥50 mg/dl. Due to the non-uniform distribution, absolute Lp(a) values were logarithmically transformed.

resultsA total of 230 patients with available Lp(a) values were included (42.6% women, mean age 66.3 ± 11.5 years, BMI 27.1 ± 4.5 kg/m2, office BP 137.1 ± 18.1/83.7 ± 11.0 mmHg, 24-hour BP 129.8 ± 14.5/79.6 ± 9.8 mmHg, Lp(a) 51.4 ± 65.3 mg/dL), among whom 32.2% had Lp(a) ≥50 mg/dl. There were significantly higher proportions of men (74.3% vs. 49.4%; P < 0.001), dyslipidaemia (97.3% vs. 75.0%; P < 0.001) and comorbidities (55.4% vs. 30.8%; P < 0.001) in patients with high Lp(a) than in those with normal Lp(a), who also received more frequently lipid lowering therapies (P < 0.001) and aspirin (P = 0.003). However, lower office systolic BP values (133.5±18.8 vs. 138.8±17.6 mmHg: P = 0.036) were observed in patients with Lp(a) ≥50 mg/dL than in those with < 50 mg/dl. Also, no significant differences for Lp(a) levels were observed among various hypertension phenotypes, as defined by office (P = 0.156) or out-of-office BP values (P = 0.065). No significant correlations were found between Lp(a) and office or out-of-office BP levels, both in treated and untreated hypertensive outpatients.

conclusionsIn our population, Lp(a) levels were not associated with either office or out-of-office BP values, irrespective of antihypertensive treatment status. The role of Lp(a) in hypertension warrants further investigation.

Indexed as

Blood PressureEssential HypertensionLipoprotein(a)AgedAntihypertensive AgentsBiomarkersFemaleHumansMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsRomeUp-RegulationAntihypertensive AgentsBiomarkersLipoprotein(a)LPA protein, humanblood pressureglobal cardiovascular risk stratificationhypertensionhypertension classificationlipoprotein(a)

Identifiers

PMID41849133
PMCPMC13222255

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.